SOURCE: Recordati

June 11, 2009 09:30 ET


MILAN, ITALY--(Marketwire - June 11, 2009) - Milan, 11 June 2009 - Recordati will be meeting investors at the Italian Investor Conference organized by Borsa Italiana which will take place in London on the 23rd and 24th of June at the London Stock Exchange (10 Paternoster Square).

Info and registration at:

Borsa Italiana - Primary Markets

Large Cap Team Continental Europe

Tel +39 02 72426034

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271),with a total staff of over 2,900, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. It has headquarters in Milan, Italy, operations in the main European countries, and a growing presence in the new markets of Central and Eastern Europe. A European field force of over 1,400 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2008 was EUR 689.6 million, operating income was EUR 144.7 million and net income was EUR 100.4 million.

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.

This information is provided by HUGIN

Contact Information

  • For further information:

    Recordati website:

    Investor Relations

    Marianne Tatschke


    e-mail: Email Contact

    Media Relations

    Claudio Rossetti (Echo Comunicazione d'Impresa)

    (39)02 62694736

    e-mail: Email Contact